Axelar (Drug Discovery) Overview
- Year Founded
-
2003
- Status
-
Out of Business
- Employees
-
8
- Latest Deal Type
-
Out of Business
Axelar (Drug Discovery) General Information
Description
Operator of a drug development company intended to develop targeted oral anti-cancer therapies. The company specializes in the research and development of anti-cancer treatments that focus on inhibitors of the insulin-like growth factor receptor and their applications in cancer, enabling the healthcare industry to facilitate cancer treatment at an affordable price.
Contact Information
Website
www.axelar.seCorporate Office
- Karolinska Institutet Science Park
- Fogdevreten 2A, Solna
- 171 65 Stockholm
- Sweden
Corporate Office
- Karolinska Institutet Science Park
- Fogdevreten 2A, Solna
- 171 65 Stockholm
- Sweden
Axelar (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 22-Oct-2021 | Completed | Out of Business | |||
| 4. Secondary Transaction - Private | 30-Mar-2015 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 13-Feb-2013 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 11-May-2011 | $20M | $20M | Completed | Generating Revenue | |
| 1. Early Stage VC | 12-Jun-2008 | Completed | Generating Revenue |
Axelar (Drug Discovery) Comparisons
Industry
Financing
Details
Axelar (Drug Discovery) Competitors (1)
One of Axelar (Drug Discovery)’s competitors is Connext, a Venture Capital-Backed company based in Seongnam-si, South Korea.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Connext | Venture Capital-Backed | Seongnam-si, South Korea |
Axelar (Drug Discovery) Patents
Axelar (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2019130194-A1 | Novel drug products of picropodophyllin | Inactive | 29-Dec-2017 | ||
| WO-2013132262-A1 | Picropodophyllin derivatives | Inactive | 09-Mar-2012 | ||
| WO-2013132263-A1 | Picropodophyllin derivatives for use in therapy | Inactive | 09-Mar-2012 | ||
| CA-2812926-A1 | Picropodophyllin monohydrate or polymorph a in cancer therapy | Inactive | 08-Oct-2010 | ||
| EP-2624828-A1 | Picropodophyllin monohydrate or polymorph a in cancer therapy | Inactive | 08-Oct-2010 | A61K31/365 |
Axelar (Drug Discovery) Signals
Axelar (Drug Discovery) FAQs
-
When was Axelar (Drug Discovery) founded?
Axelar (Drug Discovery) was founded in 2003.
-
Where is Axelar (Drug Discovery) headquartered?
Axelar (Drug Discovery) is headquartered in Stockholm, Sweden.
-
What is the size of Axelar (Drug Discovery)?
Axelar (Drug Discovery) has 8 total employees.
-
What industry is Axelar (Drug Discovery) in?
Axelar (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Axelar (Drug Discovery) a private or public company?
Axelar (Drug Discovery) is a Private company.
-
What is Axelar (Drug Discovery)’s current revenue?
The current revenue for Axelar (Drug Discovery) is .
-
How much funding has Axelar (Drug Discovery) raised over time?
Axelar (Drug Discovery) has raised $20M.
-
Who are Axelar (Drug Discovery)’s competitors?
Connext is a competitor of Axelar (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process